Interact to see
Advertisement
Advertisement
ADNRX vs FSMAX
ADNRX vs FSMAX Comparison
Open Charts ADNRX vs FSMAX
American Beacon ARK Transfmt Innov R6
Price$15.53
Change-$0.44 (-2.76%)
VolumeN/A
Net Assets167.52M
Fidelity Extended Market Index
Price$89.47
Change-$0.01 (-0.01%)
VolumeN/A
Net Assets37.61B
ADNRX vs FSMAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
ADNRX vs. FSMAX commentary
Jun 07, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Hold and FSMAX is a StrongBuy.
FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 37.6B vs. ADNRX (168M). FSMAX pays higher dividends than ADNRX: FSMAX (0.50) vs ADNRX (0.00). ADNRX was incepted earlier than FSMAX: ADNRX (5 years) vs FSMAX (14 years). ADNRX (1.13) is less costly to investors than FSMAX (0.04). ADNRX is a more actively managed with annual turnover of: 38.00 vs. FSMAX (9.00). ADNRX (0) and FSMAX (0) have matching initial minimum investment requirements. ADNRX annual gain was more profitable for investors over the last year : 28.24 vs. FSMAX (11.51).
| ADNRX | FSMAX | ADNRX / FSMAX | |
| Total Expense Ratio | 1.00 | 0.04 | 2,857% |
| Annual Report Gross Expense Ratio | 1.13 | 0.04 | 3,229% |
| Fund Existence | 5 years | 14 years | - |
| Gain YTD | -0.385 | -1.540 | 25% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 168M | 37.6B | 0% |
| Annual Yield % from dividends | 0.00 | 0.50 | - |
| Returns for 1 year | 28.24 | 11.51 | 245% |
| Returns for 3 years | 20.48 | 32.40 | 63% |
| Returns for 5 years | N/A | 51.40 | - |
| Returns for 10 years | N/A | 69.19 | - |
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement